Evidence map›Paper›PMID 33918073›Full record

ArticlePharmaceutics2021

3D Bioprinted Scaffolds Containing Mesenchymal Stem/Stromal Lyosecretome: Next Generation Controlled Release Device for Bone Regenerative Medicine.

Elia Bari, Franca Scocozza, Sara Perteghella, Marzio Sorlini, Ferdinando Auricchio, Maria Luisa Torre, Michele Conti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Elia BariDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0003-0241-0620
Franca ScocozzaDepartment of Civil Engineering and Architecture, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0003-0125-3651
Sara PerteghellaDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0003-1128-7636
Marzio SorliniPharmaExceed S.r.l., 27100 Pavia, Italy.
Ferdinando AuricchioDepartment of Civil Engineering and Architecture, University of Pavia, 27100 Pavia, Italy.
Maria Luisa TorreDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0001-8062-6836
Michele ContiDepartment of Civil Engineering and Architecture, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0003-1275-0653
University of Pavia · ITUniversity of Applied Sciences and Arts of Southern Switzerland · CH

Funding

Interreg V-A Italy-Switzerland 2014-2020 ATEx-Advanced Therapies Experiences. Project ID 637541.
6 · The paper itself

Abstract

Three-dimensional printing of poly(ε-caprolactone) (PCL) is a consolidated scaffold manufacturing technique for bone regenerative medicine. Simultaneously, the mesenchymal stem/stromal cell (MSC) secretome is osteoinductive, promoting scaffold colonization by cells, proliferation, and differentiation. The present paper combines 3D-printed PCL scaffolds with lyosecretome, a freeze-dried formulation of MSC secretome, containing proteins and extracellular vesicles (EVs). We designed a lyosecretome 3D-printed scaffold by two loading strategies: (i) MSC secretome adsorption on 3D-printed scaffold and (ii) coprinting of PCL with an alginate-based hydrogel containing MSC secretome (at two alginate concentrations, i.e., 6% or 10%

Indexed as

3D printingbone regenerative medicinebone tissue engineeringmesenchymal stem cellsMSC extracellular vesiclesMSC secretomepoly(ε-caprolactone)

Identifiers

PMID33918073
PMCPMC8070453
OpenAlexW3156656062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.